Literature DB >> 10798153

Intensive chemotherapy in children with stage IV neuroblastoma.

P Kusumakumari1, T V Ajithkumar, S Hariharan, R R Varma, V G Chellam, R Nair, M K Nair.   

Abstract

A retrospective analysis of effectiveness of sequential chemotherapy with cyclophosphamide, doxorubicin, cisplatin and etoposide in children with stage IV neuroblastoma was undertaken. Study group included 17 children of mores than one year old with median age of 3 years (range 18 months to 7 years). Fourteen were males and three females. Sites of primary tumor were abdomen in 12 patients, pelvis in 3, paravertebral in 1 and unknown in 1. Metastatic sites included bone marrow (88%), bone (82%), orbit (29.4%) and lymph node (11.7%). One patient had brain parenchymal disease and another had cerebrospinal fluid positivity for malignant cells. Fifteen of the 17 patients had major response with chemotherapy (complete response in two and partial response in 13). Ten of the 15 patients completed four courses of chemotherapy and five patients progressed while on chemotherapy and died. Only two of the ten patients, who had four courses chemotherapy are alive after 2 years. Hence the 2-year survival in this series is 11.7%. There was no toxic death in this study.

Entities:  

Mesh:

Year:  1999        PMID: 10798153     DOI: 10.1007/bf02723857

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  20 in total

1.  Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases.

Authors:  G Dini; E Lanino; A Garaventa; D Rogers; S Dallorso; C Viscoli; E Castagnola; G Manno; M Brisigotti; C Rosanda
Journal:  J Clin Oncol       Date:  1991-06       Impact factor: 44.544

Review 2.  Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma.

Authors:  N V Cheung; G Heller
Journal:  J Clin Oncol       Date:  1991-06       Impact factor: 44.544

3.  The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma.

Authors:  J J Shuster; A B Cantor; N McWilliams; J G Pole; R P Castleberry; R Marcus; T Pick; E I Smith; F A Hayes
Journal:  J Clin Oncol       Date:  1991-06       Impact factor: 44.544

4.  Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy.

Authors:  K K Matthay; H N Sather; R C Seeger; G M Haase; G D Hammond
Journal:  J Clin Oncol       Date:  1989-02       Impact factor: 44.544

5.  International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.

Authors:  G M Brodeur; R C Seeger; A Barrett; F Berthold; R P Castleberry; G D'Angio; B De Bernardi; A E Evans; M Favrot; A I Freeman
Journal:  J Clin Oncol       Date:  1988-12       Impact factor: 44.544

6.  An evaluation of the role of surgery in disseminated neuroblastoma: a report from the Children's Cancer Study Group.

Authors:  A Sitarz; J Finklestein; J Grosfeld; S Leikin; S Mc Creadie; M Klemperer; I Bernstein; H Sather; D Hammond
Journal:  J Pediatr Surg       Date:  1983-04       Impact factor: 2.545

7.  An evaluation of surgical treatment and chemotherapy of advanced neuroblastoma (stage III & IV) with special reference to proliferation kinetics of residual tumors.

Authors:  S Ogita; K Tokiwa; S Majima
Journal:  J Pediatr Surg       Date:  1985-04       Impact factor: 2.545

8.  The role of multimodal therapy in patients with local and regional neuroblastoma.

Authors:  A E Evans; G J D'Angio; C E Koop
Journal:  J Pediatr Surg       Date:  1984-02       Impact factor: 2.545

9.  Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents.

Authors:  D C West; R C Shamberger; R M Macklis; H P Kozakewich; A S Wayne; S G Kreissman; B R Korf; B Lavally; H E Grier
Journal:  J Clin Oncol       Date:  1993-01       Impact factor: 44.544

10.  Cyclophosphamide/doxorubicin vs. cisplatin/teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: a Pediatric Oncology Group Randomized Phase II study.

Authors:  N B McWilliams; F A Hayes; A A Green; E I Smith; R Nitschke; G A Altshuler; J J Shuster; R P Castleberry; T J Vietti
Journal:  Med Pediatr Oncol       Date:  1995-03
View more
  3 in total

Review 1.  Neuroblastoma in a Developing Country: Miles to Go.

Authors:  Jagdish Prasad Meena; Aditya Kumar Gupta
Journal:  Indian J Pediatr       Date:  2019-03-26       Impact factor: 1.967

2.  Real World Experience of Treating Neuroblastoma: Experience from a Tertiary Cancer Centre in India.

Authors:  Venkatraman Radhakrishnan; Anand Raja; Manikandan Dhanushkodi; T S Ganesan; G Selvaluxmy; T G Sagar
Journal:  Indian J Pediatr       Date:  2019-02-18       Impact factor: 1.967

3.  Pediatric Neuroblastoma - Impact of Nutritional Status on Complications and Outcomes.

Authors:  Ruchira Nandan; Shilpa Sharma; Minu Bajpai; Vishesh Jain; Prabudh Goel; Devendra Kumar Yadav
Journal:  J Indian Assoc Pediatr Surg       Date:  2022-03-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.